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cantly more likely than olanzapine-treated patients to ex-
perience multiple extrapyramidal symptoms. Olanzapine
patients were significantly more likely to experience
weight gain compared to risperidone and haloperidol pa-
tients. Regression models indicated that akathisia, hy-
pokinesia/akinesia, and the total number of extrapyrami-
dal symptoms were significantly associated with decreases
in the EQ-I and VAS scores from baseline to the 6-month
end-point. Weight gain and somnolence were not signifi-
cantly associated with EQ-I or VAS score changes from
baseline to the 6-month end-point. CONCLUSIONS:
The results demonstrated an inverse relationship between
adverse events and HRQoL in patients treated with an-
tipsychotics for schizophrenia. Akathisia, hypokinesia/
akinesia, and number of extrapyramidal symptoms had a
significant impact on HRQoL. The relationship between
weight gain or somnolence with HRQoL was not significant.
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OBJECTIVE: To describe and compare treatment pat-
terns of patients with schizophrenia/schizo-affective dis-
order across 15 different countries. METHODS: Exami-
nation of baseline data from a prospective, multi-centre,
double blind, randomized comparison of quetiapine and
chlorpromazine. 381 patients were recruited from 12 Eu-
ropean countries plus Canada, Australia and South Af-
rica. An economic assessment (Client Services Receipt In-
ventory) included questions about health service use in
the 3 months prior to assessment and was adapted as far
as possible to obtain internationally comparable informa-
tion. Analyses are on country-level data, irrespective of
treatment group. RESULTS: Overall, 62% of patients
had a diagnosis of paranoid schizophrenia. Mean patient
age for each country ranged from 27 to 40 years and the
proportion of males ranged between 0–85%. There were
notable variations in service use. The proportion of pa-
tients in each country who reported using any health ser-
vices ranged between 69–100%. There was a large varia-
tion in the proportions using inpatient services (range
23–100%) and average length of stay (range 7–76 days).
Take-up of community-based services also differed across
countries: 0–75% seeing community psychiatric nurses,
0–46% seeing social workers and 0–75% seeing a gen-
eral practitioner. Graphical representation of treatment
patterns using starplots showed striking similarities be-
tween Australia and the UK; and Canada and Norway.
CONCLUSION: The pre-treatment baseline data are of
interest in their own right as they provide a unique op-
portunity to examine existing treatment patterns across a
large number of countries. Sources of treatment variation
across countries can be numerous and complex, depend-
ing on national, local and patient level factors. Such interna-
tional variations should lead us to question whether results
from a study conducted in one country can easily be used to
inform mental health purchasing decisions in another.
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OBJECTIVE: Pharmacoeconomic evaluation of selective
serotonin reuptake inhibitors (SSRIs) is becoming an im-
portant issue for regulatory and marketing purposes. At
the time of the launch of the drug, decision-tree models
(i.e. Markov and Monte-Carlo) provide the most realistic
projection data available. Designed to provide a large
range of information on outcome and cost, which are
based on various assumptions, the models enable deci-
sion-makers (physician, pharmacist, HMO, regulatory
etc.) to make informed, relative decisions. METHODS:
This poster illustrates five different model structures of
associated expenses that are incurred during the treat-
ment of Depression. The branches on these models be-
come progressively complex, and are based on the fol-
lowing five factors: (1) severity of the depression, (2) rate
of compliance, (3) success/failure rate, (4) patient drop-
out from the health care system (patient having no con-
tact with any medical institution or any medical doctor),
and (5) switch in case of failure or non tolerability. Costs
were taken from the literature using different sources.
RESULTS: SSRIs could be more or less cost-effective
than tricyclic antidepressants (TCAs) depending on whether
switch, compliance, success of treatment, dropout from
the health care system and disease have been taken into
consideration. Conversely, when the same information is
derived from different sources of the same country, the
cost-effectiveness ratio is significantly affected. More-
over, sensitivity analysis does not prevent such differ-
ences in outcome. CONCLUSIONS: Caution should be
used when reviewing such data as these results indicate
the tendency for gross discrepancy to exist between dif-
ferent methods of analysis. These results thus emphasize
the need for standardized pharmacoeconomic models.
The authors make arguments in support of this endeavor.
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